Dental Membrane and Bone Graft Substitute Market - by Product Top Industry: Citagenix Inc, Straumann AG, Geistlich, Dentsply International, Zimmer Biomet, Medtronic Plc., BioHorizons IPH, Inc

Companies are developing innovative technology that provide safety, high comfort, and offers a wide range of treatment options. For instance, in 2014, Nobel Biocare Services AG had launched new creos allograft regenerative solution in the U.S. The new creos allograft portfolio consist of regenerative products in three different core products i.e. in demineralized bone matrix putty, barrier membrane, and particulate bone graft.

The new creos allograft can easily adapt to the graft site and it is a reliable and effective barrier to soft tissue ingrowth during the curative process and can easily adapt to the graft site. Moreover, in 2016, Antibe Therapeutics Inc., a subsidiary company of Citagenix Inc. had launched Neomem FlexPlus, a barrier membrane for regenerative procedures in Canada, Neomem FlexPlus a single layer collagen membrane that make surgical placement easy.

Request Sample Copy of Research @ www.coherentmarketinsights.com/insight/request-sample/1143

Dental membrane and bone graft substitute market is primarily driven by growing geriatric population. According to National Institute of Dental and Craniofacial Research, in 2014, adults from age 20 to 64 have an average of 24.92 remaining teeth and hence growing geriatric population is expected to favor the growth of the dental membrane and bone graft substitute market. According to Centers for Disease Control (CDC) NHANES Study, in 2016, the U.S. had more than 120 million people with one teeth missing and about 35 million people (i.e. approximately 10% of U.S. population) with all of their teeth missing in one or both jaws. American College of Prosthodontics (ACP) expects this number to further increase in next two decades.

For instance, in 2012 BioHorizons, Inc. launched MinerOss Cancellous, a mineralized cancellous bone allograft. MinerOss Cancellous promote rapid revascularization and gives predictable results. Moreover, in 2014, Geistlich Pharma AG received Therapeutic Goods Administration (TGA) approval for Bio-Oss in Australia. Bio-Oss particles serve as a scaffold for new bone and results in predictable bone regeneration and significantly improves clinical attachment gain and pocket depth reduction in periodontal surgery. Furthermore, in 2011, in Japan, company received marketing authorization for Geistlich Bio-Oss.

For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/market-insight/dental-membrane-and-bone-graft-substitute-market-1143

Some of the major players operating in the dental membrane and bone graft substitute market include Citagenix Inc, Straumann AG, Geistlich, Dentsply International, Zimmer Biomet, Medtronic Plc., BioHorizons IPH, Inc., ACE Surgical Supply Company, Inc., RTI Surgical, Inc., and Osteogenics Biomedical.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.